Research Center

Ortho Illinois has long held a commitment to continuing medical education and providing university-level care.  In 2006, it was a natural next step to formalize a program that allows our physicians to participate in the process that contributes to medical research and makes revolutionary new products and treatments possible.

Be a part of our clinical studies:

Printable Research Participant Flyer

Yes! I want to know more about being a research study patient! (Online submission)

Studies Currently Active and Enrolling

1. Radomized, Double-Blind, Placebo-Controlled, Phase2/Phase 3 Multicenter Study to Evaluate the Efficacy and Safety of IP in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus – Dr. Amrit Anand and Dr. Husna Siddiqui, Elgin Office
2. A Randomized, Controlled Pragmatic Phase 3b/4 Study of IP in Patients with Rheumatoid Arthritis – Dr. Amrit Anand and Dr. Husna Siddiqui, Elgin Office
3. Rheumatoid Arthritis Registry – Dr. Andrew Jasek and Dr. Saad Tariq, Riverside Office in Rockford; and Dr. Amrit Anand, Elgin Office
4. Phase 3, Randomized, Double-Blind Study Comparing IP to Placebo and to Adalimumad in Subjects with Active Psoriatic Arthritis (PsA) – Dr. Andrew Jasek, Primary Investigator, Riverside Office in Rockford
5. Phase 3, Randomized, Double-Blind Study Comparing IP to Placebo in Subjects with Active Psoriatic Arthritis (PsA) – Dr. Saad Tariq, Primary Investigator, Riverside Office in Rockford
6. Phase 3b/4, Randomized, Controlled Pragmatic Study of IP in Patients with Rheumatoid Arthritis – Dr. Andrew Jasek, Principal Investigator, Riverside Office in Rockford
7. A multicentre, prospective clinical study analyzing outcomes of shoulder arthroplasty with SMR TT Hybrid Glenoid with or without SMR Cementless Finned Short Stem – Dr. Rolando Izquierdo, Principal Investigator, Algonquin Office
8. Longitudinal Outcome Study: Subchondroplasty Procedure of the Hip – Dr. Geoffrey Van Thiel, Primary Investigator, Roxbury Office in Rockford
9. Phase 4, Placebo-controlled Study Evaluating the Efficacy and Safety of Investigational Product Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease – Dr. Saad Tariq, Principal Investigator, Riverside Office in Rockford
10. Phase 4, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Investigational Product in Subjects with Early Oligoarticular Psoriatic Arthritis – Dr. Saad Tariq, Primary Investigator, Riverside Office in Rockford
11. Open Label, Multi-Center, Retrospecitive and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiographic Outcomes – Dr. Scott Trenhaile, Roxbury Office in Rockford
12. Post Market Unicompartmental Knee Study – Dr. Mark Oyer, Primary Investigator, Riverside Office in Rockford
13. Evaluation of safety and efficacy of a resorbable collagen implant in treatment of High Grade Partial Thickness Tears:  A prospective, multicenter, randomized, controll trial – Dr. Scott Trenhaile, Principal Investigator, Roxbury office in Rockford
14. A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE – Dr. Saad Tariq, Principal Investigator, Riverside Office in Rockford
15. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of IP Compared to Placebo in Patients with Moderately to Severely Active Systemic Lupus Erythematosus – Dr. Zhe Liang, Principal Investigator, Riverside Office in Rockford
16. A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of IP Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor – Dr. Saad Tariq, Principal Investigator, Riverside Office in Rockford
17. Prospective, Multi-Center, Post-Market Clinical Follow-up Study to Evaluate Safety and Performance of the IP in Shoulder Rotator Cuff Tendon Repair – Dr. Scott Trenhaile, Principal Investigator, Roxbury Office in Rockford
18. Open Label, Multi-Center, Retrospective and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiographic Outcomes – Dr. Rolando Izquierdo, Algonquin Office

---

About Clinical Research:

Clinical research studies are biomedical or health-related studies that involve patients with a targeted diagnosis. Depending on the specific study, there are usually 50-100 sites nationally or internationally participating in a particular study. Sites are carefully selected based on state-of-the-art diagnostic and facility criteria and by the commitment demonstrated by the physicians involved in top quality patient care.

By participating in national and international clinical research studies at the Phase II-IV levels, Ortho Illinois physicians have access to new treatment options for patients on a local level who have not experienced improvement through other treatments.

Currently, Ortho Illinois has executed over 80 clinical research and post market studies. We are proud to participate in the first-in-class drug studies for the treatment of rheumatoid arthritis, notably Xejanz® and Otezla®.  We seek advanced medical device studies including biodegradable materials or using the body’s own stem cells to heal joint damage.   By gaining years’ of experience using cutting edge technologies, our physicians already have the expertise you desire once a new drug or device is approved by the FDA.

In addition to expanding physicians’ experience and knowledge, being in a clinical trial offers great benefits to patients.  Study participants gain access to new research treatments before FDA approval or availability, receive more services, are assessed more frequently, and have a more active role in their health care.  Participating in a research study offers financial as well as health benefits, especially for those patients with high co-pays or who do not have healthcare coverage.  All laboratory, medication, and physician costs specific to the study are covered for the patient participant by the company conducting the study.

For further information about research studies contact:

Catherine M. Ayala, PharmD, Clinical Research Director at 815-381-7482, catherine.ayala@orthoillinois.com.

Heather Hackman, ROT, Clinical Research Coordinator, at 815-381-7468, heather.hackman@orthoillinois.com

Rubinder Kaur, Clinical Research Coordinator, at 815-381-7457, rubinder.kaur@orthoillinois.com